Redefining respiratory care together

NuvoAir respiratory platform is designed to assist patients and physicians in preventing clinical deterioration from respiratory exacerbations. NuvoAir deliver insights into how patients’ lung health is developing overtime so that physicians can proactively take the most appropriate clinical decisions.

Severe Asthma

Use of an asthma management plan, with regular monitoring of asthma symptoms and lung function, can detect the early signs of worsening control.1

However, paper-based plans are inconvenient to patients, and have lower persistence rates than electronic plans2 , with data collected in paper diaries being less reliable than electronic data.3

NuvoAir platform combines a personalized asthma management plan with lung function measurement to support patients in managing their asthma more effectively.

Our platform also incorporates air quality and weather data to advise patients to pay extra care when going out. The early stages of worsening in asthma control could be detected by our personalised algorithms.

Chronic obstructive
pulmonary disease (COPD)

Lung function monitoring is considered cornerstone in the management of COPD. FEV1 correlates with exercise capacity, activities of daily living, and quality of life in COPD patients.4,5 Multiple studies have correlated FEV1 or FEV1 decline as strong predictors of the risk of COPD exacerbation.6

This emphasizes the need to recognize these patients, since COPD exacerbations are the single most expensive aspect of COPD care, and multiple effective therapeutic interventions are available to reduce exacerbations.

NuvoAir collects mMRC, lung function data and activity levels in patients with COPD. Although, pulmonary rehabilitation is effective in inducing behavioural change to encourage patients to be more active, access and availability is limited; self-management program, using a smartphone app, can be an effective substitute in patients with COPD.8

Cystic Fibrosis (CF)

Patients with cystic fibrosis need regular assessments to monitor their disease progression, with guidelines recommending reviews every 3–6 months in adults, with assessments to include spirometry and weight measurement (to identify patients with weight loos due to poor nutrition).9

Attendance at specialist clinics for these assessments is not only inconvenient and time-consuming for your patients, but puts them at increased risk of infection. Remote monitoring is therefore recommended.

NuvoAir permits your patients to track their lung function, CF symptoms , and weight changes and to understand how their condition progresses over time. Personalized algorithms inform you and your patients when their condition is deteriorating so you can take action.

In a study with the Royal Brompton Hospital in London, UK, the use of NuvoAir to run a virtual consultation service significantly reduced both booked and urgent face-to-face visits, with acceptability rated very highly by patients. 10

Interstitial pulmonary
fibrosis (IPF)

A decline in forced vital capacity (FVC) is a key marker of disease progression in IPF,11 but the inherent variability in this assessment12 means that infrequent assessments performed at standard clinic visits may not detect this decline.

Regular home spirometry can be useful both in early detection of patients with rapidly declining FVC, and in monitoring response to therapies.13

NuvoAir Home can support your hospital in identifying which patients are rapid decliners, and who therefore need additional support. Furthermore, in a study in patients with a range of respiratory conditions, including interstitial lung disease, there was high concordance between results from the NuvoAir spirometer and a standard office-based spirometer.14

Muscular Distrophy

Respiratory complications are a major cause of morbidity and mortality in muscular dystrophy.15

However, deteriorating lung function is not always accompanied by worsening symptoms, and serial lung function assessments are therefore a critical component of clinical management.15

NuvoAir incorporates reminders to patients to perform spirometry on a regular basis, and can be easily programmed to give both you and your patients a warning of excessive lung function decline.

NuvoAir has conducted many clinical trials in both ALS and DMD demonstrating its technology is highly suitable for this patient population.

Lung Transplant

A persistent fall in forced expiratory volume in 1 second is the hallmark of chronic rejection following lung transplantation.16

Home spirometry, especially as part of a telemedicine program, can help to identify this decline early, potentially improving outcomes.17,18

NuvoAir incorporates reminders to patients to perform spirometry on a regular basis, and can be easily programmed to give both you and your patients a warning of excessive lung function decline.

Clinically relevant data at your fingerprints

NuvoAir Portal makes the data always accessible in real time to the clinical team so they can take proactively the most appropriate clinical decisions.

1. Global Initiative For Asthma. Global strategy for asthma management and prevention. 2020
2. Cruz-Correia R, Fonseca J, Lima L, et al. Web-based or paper-based self-management tools for asthma--patients’ opinions and quality of data in a randomized crossover study. Stud Health Technol Inform 2007; 127: 78–89.
3. Araújo L, Jacinto T, Moreira A, et al. Clinical efficacy of web-based versus standard asthma self-management. J Investig Allergol Clin Immunol 2012; 22: 28–34.
4. McGlone S, Venn A, Walters EH, Wood-Baker R. Physical activity, spirometry and quality-of-life in chronic obstructive pulmonary disease. J Chron Obst Pulm Dis 2006;3(2):83-88.
5. Plankeel JF, McMullen B, MacIntyre NR. Exercise outcomes after pulmonary rehabilitation depend on the initial mechanism of exercise limitation among
6. Fan VS, Ramsey SD, Make BJ, Martinez FJ. Physiologic variables and functional status independently predict COPD hospitalizations and emergency department visits in patients with severe COPD. J Chron Obstr Pulm Dis 2007;4(1):29-39
7. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2020. (accessed May 23, 2020).
8. Park SK, Bang CH, Lee SH. Evaluating the effect of a smartphone app-based self-management program for people with COPD: A randomized controlled trial. Appl Nurs Res 2020; 52. DOI:10.1016/j.apnr.2020.151231.
9. National Institute for Health and Care Excellence. Cystic fibrosis: diagnosis and management. NICE guideline [NG78]. 2017.
10 ePS1.07 Patient experience of virtual consultations: survey results. Journal of Cystic Fibrosis, Volume 19, Supplement 2, June 2020, Page S39"
11. Zappala CJ, Latsi PI, Nicholson AG, et al. Marginal decline in forced vital capacity is associated with a poor outcome in idiopathic pulmonary fibrosis. Eur Respir J 2010; 35: 830–5.
12. Raghu G, Collard HR, Egan JJ, et al. An Official ATS/ERS/JRS/ALAT Statement: Idiopathic Pulmonary Fibrosis: Evidence-based Guidelines for Diagnosis and Management. Am J Respir Crit Care Med 2011; 183: 788–824.
13. Russell AM, Adamali H, Molyneaux PL, et al. Daily home spirometry: An effective tool for detecting progression in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2016; 194: 989–97.
14. Exarchos KP, Gogali A, Sioutkou A, Chronis C, Peristeri S, Kostikas K. Validation of the portable Bluetooth® Air Next spirometer in patients with different respiratory diseases. Respir Res 2020; 21: 79.
15. Birnkrant DJ, Bushby K, Bann CM, et al. Diagnosis and management of Duchenne muscular dystrophy, part 2: respiratory, cardiac, bone health, and orthopaedic management. Lancet Neurol 2018; 17: 347–61.
16. Verleden GM, Raghu G, Meyer KC, Glanville AR, Corris P. A new classification system for chronic lung allograft dysfunction. J. Hear. Lung Transplant. 2014; 33: 127–33.
17. Fadaizadeh L, Najafizadeh K, Shajareh E, Shafaghi S, Hosseini M, Heydari G. Home spirometry: Assessment of patient compliance and satisfaction and its impact on early diagnosis of pulmonary symptoms in post-lung transplantation patients. J Telemed Telecare 2016; 22: 127–31.
18. Robson KS, West AJ. Improving survival outcomes in lung transplant recipients through early detection of bronchiolitis obliterans: Daily home spirometry versus standard pulmonary function testing. Can J Respir Ther CJRT = Rev Can la Ther Respir RCTR 2014; 50: 17–22.

Join NuvoAir today

We work with leading pharmaceutical companies, insurance plans and healthcare systems to offer NuvoAir at no cost to people with respiratory problems. Answer a few quick questions to see how we can start your journey with NuvoAir.